Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876157 | 0.91 | KLKB1 (0.43) | KLKB1L3MBTL1LMNATRPM8KDM4E | |
| SCHEMBL12875851 | 0.89 | RARA (0.41) | KLKB1L3MBTL1LMNARXFP1TRPM8 | |
| SCHEMBL12875936 | 0.89 | RARA (0.43) | KLKB1L3MBTL1LMNATRPM8KDM4E | |
| SCHEMBL12875878 | 0.87 | KLKB1 (0.40) | KLKB1L3MBTL1LMNATRPM8KDM4E | |
| SCHEMBL12875928 | 0.87 | KLKB1 (0.56) | KLKB1L3MBTL1LMNARXFP1KDM4E | |
| SCHEMBL1198412 | 0.87 | ALDH1A1 (0.48) | KLKB1KDM4EALDH1A1MAPTPPARD | |
| SCHEMBL12876169 | 0.84 | KLKB1 (0.39) | KLKB1L3MBTL1LMNATRPM8KDM4E | |
| SCHEMBL12875881 | 0.84 | KLKB1 (0.39) | KLKB1L3MBTL1LMNATRPM8KDM4E | |
| SCHEMBL12875963 | 0.83 | PPARG (0.39) | KLKB1L3MBTL1TRPM8KDM4EALDH1A1 | |
| SCHEMBL12876154 | 0.82 | MAPT (0.41) | KLKB1LMNATRPM8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | KLKB1 3765/4885L3MBTL1 4726/4885LMNA 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.